Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
((Chloroquine OR Hydroxychloroquine) AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
3,969 results
  • Slight High-Frequency Hearing Loss, Effect of COVID-19 or Hydroxychloroquine Usage? [Journal Article]
    Otol Neurotol. 2022 Aug 17 [Online ahead of print]Rahimi V, Rouhbakhsh N, Manshadi SAD
  • CONCLUSIONS: Slight hearing loss was seen in patients with COVID-19 with or without HCQ. Also, hearing thresholds in the HCQ+ group did not show a significant difference compared with the HCQ- group. Nevertheless, it seems that more damage is done to the hair cells of patients with HCQ intake than in other patients. Hence, the ototoxicity effect of high doses of HCQ use in the COVID-19 patients should be considered. A relative improvement in the hearing was seen over time in both patient groups.
  • Lived experiences of recovered COVID-19 persons in Nigeria: A phenomenological study. [Journal Article]
    PLoS One. 2022; 17(8):e0268109.Okonofua FE, Ntoimo LFC, … Balogun J
  • CONCLUSIONS: We conclude that persons who recovered from COVID-19 in Nigeria had varied experiences relating to the mode of infection, the clinical features, methods of treatment, and psychosocial effects of the virus. These experiences would be useful for designing and implementing appropriate interventions, policies, and programs for managing the pandemic in the country.
  • How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice. [Review]
    Intern Med J. 2022 Aug 15 [Online ahead of print]Fairley JL, Nikpour M, … Wicks IP
  • Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long-term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases inc…
  • Neutrophil autophagy and NETosis in COVID-19: perspectives. [Review]
    Autophagy. 2022 Aug 11 [Online ahead of print]Zhang R, Sun C, … Wang J
  • The COVID-19 pandemic has caused substantial losses worldwide in people's lives, health, and property. Currently, COVID-19 is still prominent worldwide without any specific drug treatment. The SARS-CoV-2 pathogen is the cause of various systemic diseases, mainly acute pneumonia. Within the pathological process, neutrophils are recruited to infected sites, especially in the lungs, for the first st…
  • Comparative-effectiveness research of COVID-19 treatment: a rapid scoping review. [Review]
    BMJ Open. 2022 06 03; 12(6):e045115.Pham B, Rios P, … Tricco AC
  • CONCLUSIONS: This rapid scoping review characterised a growing body of comparative-effectiveness primary studies and evidence syntheses. The results suggest future studies should focus on children, elderly ≥65 years of age, patients with mild symptoms, outpatient treatment, multimechanism therapies, harms and active comparators. The results also suggest that future living evidence synthesis and network meta-analysis would provide additional information for decision-makers on managing COVID-19.
  • Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. [Review]
    Eur J Epidemiol. 2022 Aug 09 [Online ahead of print]García-Albéniz X, Del Amo J, … Hernán MA
  • CONCLUSIONS: A benefit of HCQ as prophylaxis for COVID-19 cannot be ruled out based on the available evidence from randomized trials. However, the "not statistically significant" findings from early prophylaxis trials were widely interpreted as definite evidence of lack of effectiveness of HCQ. This interpretation disrupted the timely completion of the remaining trials and thus the generation of precise estimates for pandemic management before the development of vaccines.
  • Overview of Hydroxychloroquine and Remdesivir on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [Review]
    J Heterocycl Chem. 2022 Jul 28 [Online ahead of print]Kabi AK, Pal M, … Roy M
  • The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the ongoing pandemic named COVID-19 which causes a serious emergency on public health hazards of international concern. In the face of a critical medical emergency, repositioning of drugs is one of the most authentic options to design an adequate treatment for infected patients immediately. In this strategy, Remdesivir …
  • Management of neonatal sepsis with COVID-19 infection in a premature newborn - A case report. [Case Reports]
    J Neonatal Nurs. 2022 Aug 02 [Online ahead of print]Kaveh M, Sadatinejad SM
  • CONCLUSIONS: The basics of treatment for neonatal COVID-19 is supportive care. Some studies have treated infants with various drugs such as Hydroxychloroquine, Favipiravir, and Remedsivir; however, in our case, a 5-day-old baby boy was treated with corticosteroids and IVIg. We achieved good outcomes after 2 weeks of treatment with dexamethasone 0.3 mg/kg per day and IVIg 2 g/kg/day (for 3 days). It appears that these treatments, along with adjuvant ventilation and the administration of endotracheal surfactant, can improve a patient's general condition.
  • Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study. [Randomized Controlled Trial]
    BMC Med Res Methodol. 2022 08 06; 22(1):216.Sirkis T, Jones B, Bowden J
  • CONCLUSIONS: Using response-adaptive randomisation within RECOVERY could have increased the number of patients receiving the optimal COVID-19 treatment during the trial, while reducing the number of patients needed to attain the same study power as the original study. This would likely have reduced patient deaths during the trial and lead to dexamethasone being declared effective sooner. Deciding how to balance the needs of patients within a trial and future patients who have yet to fall ill is an important ethical question for the trials community to address. Response-adaptive randomisation deserves to be considered as a design feature in future trials of COVID-19 and other diseases.
  • Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers. [Journal Article]
    PLoS One. 2022; 17(8) Reus YA, Hagedoorn P, … Akkerman OW
  • CONCLUSIONS: Dry powder HCQ inhalations were well tolerated by the participants, except for transient bitter taste in all participants and minor coughing irritation. There was no significant change in QTc-interval or drop in FEV1 post inhalation. The serum HCQ concentration remained below 10 μg/L in all samples.Single doses of inhaled dry powder HCQ up to 20 mg are safe and well tolerated. Our data support that further studies with inhaled HCQ dry powder to evaluate pulmonary pharmacokinetics and efficacy are warranted.
New Search Next